FBLG NASDAQ
FibroBiologics, Inc. Common Stock
1W: -19.7%
1M: -14.5%
3M: -55.8%
YTD: +161.4%
1Y: -4.5%
$0.65
+0.02 (+3.72%)
Weekly Expected Move ±14.3%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.4M
52W Range0.62-13.16
Volume61,942
Avg Volume212,490
Beta1.17
Dividend—
Analyst Ratings
Company Info
CEOPeter O'Heeron
Employees15
SectorHealthcare
IndustryBiotechnology
IPO Date2024-02-01
Websitefibrobiologics.com
455 East Medical Center Boulevard
Houston, TX 77598
US
Houston, TX 77598
US
281 651 5150
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Latest News
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
12 Health Care Stocks Moving In Wednesday's After-Market Session
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Niklas Victoria Nino | A-Award | 30,803 | $0.75 | 2026-06-23 |
| Hoffman Robert E. | A-Award | 30,803 | $0.75 | 2026-06-23 |
| Cilento Richard C. J | A-Award | 30,803 | $0.75 | 2026-06-23 |
| Link Matthew | A-Award | 30,803 | $0.75 | 2026-06-23 |
| O'HEERON PETE | A-Award | 92,410 | $1.38 | 2026-05-04 |